. Author manuscript; available in PMC: 2021 Nov 10.

Published in final edited form as: J Investig Med. 2020 Aug 31;68(8):1364–1369. doi: 10.1136/jim-2020-001373

Table 3.

CMR and serum biomarker results for all patients post-chemotherapy

	Median (range)
MRI
LVEDV (mL/m²)	93 (51.6–125)
LVEF (%)	58 (49.1–71.2)
ECV—4 chamber (%)	24.9 (20.4–36.0)
ECV—short axis (%)	24.8 (21.2–32.3)
Late gadolinium enhancement	None
Patients with at least one abnormal ECV ROI	14
Serum biomarkers
NT-pro-BNP (pg/mL)	49.9 (0.8–302.6)
Troponin I (ng/mL)	<0.02
MPO	0
ST2 (ng/mL)	26 (15.0–60.0)

ECV, extracellular volume; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; MPO, myeloperoxidase; NT-pro-BNP, N-terminal brain natriuretic peptide; ROI, region of interest; ST2, interleukin 1 receptor-like 1 protein.